High-dose donepezil or memantine: Next step for Alzheimer's disease?

Current Psychiatry

Volumn 11, Issue 6, 2012, Pages 20-29

  Singh, Indrapal ^a   Grossberg, George T ^b  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; RIVASTIGMINE; TACRINE;

ABDOMINAL PAIN; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY; ARTICLE; BACKACHE; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONTUSION; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOTENSION; INFLUENZA; INSOMNIA; IRRITABILITY; LIVER TOXICITY; NAUSEA; PATIENT COMPLIANCE; RHINOPHARYNGITIS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; URINE INCONTINENCE; VOMITING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84864302966     PISSN: 15378276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Alzheimer's Association, Thies W, Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 2011;7(2):208-244.
2. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119-1122.
3. Alzheimer's Disease Education and Referral Center. Alzheimer's disease medications. http://www.nia.nih.gov/alzheimers/publication/alzheimers-diseasemedications-fact-sheet. Accessed May 10, 2012.
4. Osborn GG, Saunders AV. Current treatments for patients with Alzheimer disease. J Am Osteopath Assoc. 2010;110(9 suppl 8):S16-S26.
5. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379-397.
6. Cummings JL. Alzheimer's disease. N Engl J Med. 2004; 351(1):56-67.
7. Tariot PN, Farlow MR, Grossberg GT, et al; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291(3):317-324.
8. Xiong G, Doraiswamy PM. Combination drug therapy forzheimer 's disease: what is evidence-based, and what is not? Geriatrics. 2005;60(6):22-26.
9. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234-1251.
10. Periclou A, Hu Y. Extended-release memantine capsule (28 mg, once daily): a multiple dose, open-label study evaluating steady-state pharmacokinetics in healthy volunteers. Poster presented at 11th International Conference on Alzheimer's Disease; July 26-31, 2008; Chicago, IL.
11. Grossberg GT, Manes F, Allegri R, et al. A multinational, randomized, double-blind, placebo-controlled, parallelgroup trial of memantine extended-release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer's disease. Poster presented at 11th International Conference on Alzheimer's Disease; July 26-31, 2008; Chicago, IL.
12. Geula C, Mesulam MM. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb Cortex. 1996;6(2):165-177.
13. Whitehouse PJ. The cholinergic deficit in Alzheimer's disease. J Clin Psychiatry. 1998;59(suppl 13):19-22.
14. Teipel SJ, Flatz WH, Heinsen H, et al. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain. 2005;128(11):2626-2644.
15. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am J Health Syst Pharm. 1997;54(24):2805-2810.
16. Homma A, Imai Y, Tago H, et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebocontrolled, randomized trial. Dement Geriatr Cogn Disord. 2008;25(5):399-407.
17. Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry. 2004;19(7):624-633.
18. Nozawa M, Ichimiya Y, Nozawa E, et al. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. Psychogeriatrics. 2009;9(2):50-55.
19. Kuhl DE, Minoshima S, Frey KA, et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol. 2000;48(3):391-395.
20. Bohnen NI, Kaufer DI, Hendrickson R, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005;76(3): 315-319.
21. Doody RS, Corey-Bloom J, Zhang R, et al. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008;25(2):163-174.
22. Aricept [package insert]. Woodcliff Lake, NJ: Eisai Co.; 2012.
23. Schwartz LM, Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ. 2012;344:e1086. doi: 10.1136/bmj.e1086.
24. Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15(6):e22-e33.
25. Periclou A, Ventura D, Rao N, et al. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther. 2006;79(1):134-143.
26. Atri A, Shaughnessy LW, Locascio JJ, et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008; 22(3):209-221.